Science & Research

Dr. Eliaz and his team partner with renowned institutes including Harvard, Columbia, and others to investigate integrative approaches in the treatment of cancer and chronic conditions. In addition, many of Dr. Eliaz’s unique preparations have been studied independently by third-party groups, with peer-reviewed results demonstrating unparalleled benefits against cancer, fibrotic diseases and more.

The unique form of Modified Citrus Pectin developed by Dr. Eliaz is recognized as the only commercially available galectin-3 blocker, substantiated by more than 40 published studies in cancer, cardiovascular disease, chronic kidney disease, and other pro-inflammatory, degenerative conditions.

Summaries below include links to research abstracts.

Published Research

Modified Citrus Pectin

Modified Citrus Pectin Research

2018 Clinical Study (Interim Results): Modified Citrus Pectin Halts Biochemically Relapsed Prostate Cancer

2018 Preclinical Study: Modified Citrus Pectin Inhibits Colon Cancer Migration via Galectin-3 Inhibition

2018 Practice Survey: Modified Citrus Pectin at Top of List for Naturopathic Treatment of Thoracic Cancer

2018 Preclinical Study: Modified Citrus Pectin Enhances Radiotherapy Against Prostate Cancer

2018 Preclinical Study: Modified Citrus Pectin Increases Antioxidant Activity and Reduces Oxidative Stress in Hypertension Model, through Inhibition of Galectin-3

2018 Preclinical Study: Modified Citrus Pectin Inhibits Bladder Tumor Growth through Downregulation of Galectin-3

2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Mitigates Diet-Induced Cardiac Lipotoxicity and Reduces Mitochondrial Damage

2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Reduces Inflammatory Mediators and Decreases Kidney Damage in Spontaneous Hypertension Model

2017 Preclinical Study: Modified Citrus Pectin Protects Vascular Tissue against Abdominal Aortic Aneurism by Decreasing Galectin-3 and Inflammatory Cytokine Expression

2017 Preclinical Study: Modified Citrus Pectin Combined with Alginate and Live Probiotic, Lactobacillus acidophilus Offered Benefit to Improve the Intestinal Lactobacilli Microbiota in Healthy Host

2017 Observational Study: Modified Citrus Pectin Listed Among Researched Nutrients with Anti-Carcinogenic Properties to Reduce CTC Count

2017 Preclinical Study: Modified Citrus Pectin Protects Against Shiga Toxin Adhesion and Cytotoxicity, via Prebiotic Actions

2017 Preclinical Study: Modified Citrus Pectin Reduces Size of Atherosclerotic Lesions, via Inhibition of Galectin-3

2017 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Cardiac Remodeling, Fibrosis and Inflammation Associated with Early Aortic Stenosis

2017 Preclinical Study: Modified Citrus Pectin and Pure Honokiol Offer Synergistic Antioxidant and Anti-inflammatory Effects, Reduce Tumor Necrosis-α (TNF-α), Nuclear factor-kappa B, Cyclooxygenase-II, and Lipid Peroxidation

2017 Preclinical Study: Modified Citrus Pectin Gives Additive Antibacterial Effect in Combination with Cefotaxime Against Staphylococcus aureus Infection

2017 Preclinical Study: Galectin-3 inhibition with Modified Citrus Pectin Blocks Inflammation, Fibrosis and Calcification in Aortic Valves

2016 Preclinical Study: Modified Citrus Pectin Reduces Renal Fibrosis, Inflammation and Damage, Through Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Blocks Inflammation and Fibrosis and Prevents Calcification in Aortic Stenosis, via Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Prevents Adipose (Fat)Tissue Remodeling in Obesity, via Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Stops Progression of Liver Fibrosis Through Antioxidant Effect, Galectin-3 Inhibition and Induction of Apoptosis

2016 Preclinical Study: Modified Citrus Pectin Inhibits Growth and Metastasis of Gastrointestinal Cancer Cells

2016 Preclinical Study: Modified Citrus Pectin Prevents Left Ventricle Dysfunction and Cardiac Fibrosis, through Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus pectin Suppresses Neuropathic Pain and Decreases Proinflammatory Mediators Following Peripheral Nerve Injury, via Inhibition of Galectin-3

2015 Preclinical Study: Modified Citrus Pectin Prevents Obesity-Related Cardiovascular Remodeling, through Inhibition of Galectin-3

2015 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Inhibit Cardiac Inflammation and Fibrosis in Experimental Hypertension

2015 Preclinical Study: Modified Citrus Pectin and Alginate Probiotic Combination offer Chemopreventive Effect against Colon Cancer Cells

2015 Preclinical Study: Modified Citrus Pectin Prevents Cardiac and Kidney Fibrosis, via Inhibition of Galectin-3

2013 Preclinical Study: Modified Citrus Pectin Reverses Vascular Hypertrophy and Fibrosis, via Inhibition of Galectin-3

2013 Preclinical Study: Modified Citrus Pectin Traverses Small Intestinal Epithelium Demonstrating increased Bioavailability

2013 Preclinical Study: Modified Citrus Pectin Demonstrates Synergistic Effect with Polybotanical Compounds for Breast and Prostate Cancer

2012 Preclinical Study: Synergistic Effects of Modified Citrus Pectin and Doxorubicin against Prostate Cancer Cells

2011 Preclinical Study: Modified Citrus Pectin Reduces Kidney Disease Severity by Reducing Galectin-3 Expression

2011 Preclinical Study: Modified Citrus Pectin Activates Powerful Immune Response

2011 Preclinical Study: Activation and Induction of Natural Killer Cell Activity Against Leukemia Cells with Modified Citrus Pectin

2010 Preclinical Study: Modified Citrus Pectin Inhibits Prostate Cancer

2010 Review: Modified Citrus Pectin Anti-Metastatic Properties

2009 Preclinical Study: Modified Citrus Pectin Binds to Galectin-3

2008 Clinical Study: The Role of Modified Citrus Pectin as an Effective Chelator of Lead in Children Hospitalized with Toxic Lead Levels

2007 Clinical Study: The Role of Modified Citrus Pectin/Alginates in Heavy Metal Chelation and Detoxification

2007 Clinical Study: Modified Citrus Pectin Clinical Benefit in Patients with Advanced Solid Tumors

2006 Clinical Study: The Effect of Modified Citrus Pectin on the Urinary Excretion of Toxic Elements

2003 Clinical Study: Modified Citrus Pectin (MCP) Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study

To Read More, visit: PubMed

 

Share

Powered by ThreeSided Studios